Nasal polyps are the type of lesions that arises from the mucosa of the nasal cavity. The cause of nasal polyps is still unknown. According to researchers, chronic inflammation in the nose and nasal sinuses are responsible for the occurrence of nasal polyps. Nasal polyps can be symptomatized by the runny nose, postnasal drip, absent sense of smell, facial pain, pain in upper teeth, snoring, persistent stuffiness, and sense of pressure over the forehead. The risk factors for nasal polyps include asthma, allergic fungal sinusitis, cystic fibrosis, chronic sinus infection, hay fever and aspirin sensitivity. The complication associated with nasal polyps are the infection (bacterial or viral), recurrent polyps and bleeding. Sanofi SA is in the process of developing SAR231893 as an interleukin 4 receptor type I antagonist for the treatment of nasal polyps. GlaxoSmithKline plc is in the process of developing mepolizumab as interleukin 5 inhibitor for the treatment of nasal polyps. Some of the companies having the pipeline of nasal polyps include Sanofi SA, Pfizer, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.